In terms of physicians reporting adverse events, I think you'd want to encourage physicians to do that for all drugs that they think there's an issue with.
My point was around the use of some of these administrative databases, as Steven described, which would allow us to kind of data mine to look for adverse events for every single drug that's approved. Sometimes if you look, you're going to find stuff that looks like it's there, but it may not actually be accurate.
And there's a cost, in terms of both personnel and the cost of doing all these things. So my sense is that if there's a new drug in a class, if there's anything from the initial studies that suggests there's a concern, if someone reports an adverse report, one would want to look at those drugs with the administrative data.
If it were another of a kind, a new statin, as Steven said, to lower cholesterol, and I had a limited budget and time, I'm not sure I'd spend my time looking at that drug. You have to make some kinds of reasonable decisions, it seems to me.